



H.C WAINWRIGHT GENE THERAPY AND GENE EDITING CONFERENCE


March 30, 2022

FORWARD-LOOKING STATEMENTS


This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbour provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding possible or assumed future results of operations, business strategies, research and development plans, regulatory activities, market opportunity, competitive position and potential growth opportunities are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our reliance on the maintenance on certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of the COVID-19 pandemic on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our future clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.



Future Vision



CENTURY'S EMERGING FRANCHISES



B cell malignancies

- **CNTY-101:** Lead product candidate, CD19 targeted CAR-iNK
- **CNTY-102:** First $\gamma\delta$ iT candidate, multi-specific (CD19 + CD79b) CAR-iT

Next generation cell therapy – expected to be first product to enter the clinic with edits designed to avoid all major pathways of rejection

Franchise of iNK and iT cell therapies anticipated to address all patient subtypes, provides optionality



Glioblastoma

- **CNTY-103:** Multi-specific (CD133+ EGFR) CAR iNK for recurrent GBM
- **Follow-on candidate**

Multi-tumor antigen targeting addresses heterogeneity in GBM tumor cells

iNK product with local administration may minimize toxicity



Solid tumors

- **Future candidate** expected to be announced 2022


Leverage $\gamma\delta$ iT platform to target challenging solid tumors

Pre-clinical data shows dose dependent activity, low risk of CRS and GvHD

CNTY-101: NEXT GENERATION CD19 TARGETED PRODUCT

HIGHLY DIFFERENTIATED PROFILE

Allo-Evasion™ edits




CNTY-101

First cell product candidate with 6 gene edits introduced with CRISPR-HDR


ELIPSE-1: PHASE 1 STUDY

- Study expected to enroll first patient by YE
- Designed to maximize learnings
- Potential to dose as needed with single LD cycle
- Effect of Allo-Evasion on iNK persistence after multiple doses

ELIPSE-1 Schema (Schedule B)



CNTY-103: FIRST PROGRAM IN CNS MALIGNANCIES




- **Targeting EGFR+ GBMs:** Provides better coverage intended to ensure maximum tumor clearance
- **Targeting CD133+ GBMs:** Clears functionally relevant treatment-resistant tumor cells

UNIQUELY POSITIONED TO ADDRESS CHALLENGES OF GBM

Challenge	Century's Solution
Trafficking	Local delivery with Ommaya reservoir
Heterogeneity	Targeting EGFR / EGFRvIII and CD133 (functional marker of treatment-resistant GBM cells)
Toxicity	Minimize risks like CRS with iNK
Persistence	Potential to dose as needed

CENTURY'S iPSC PLATFORM UNLOCKS TRANSFORMATIONAL POTENTIAL OF ALLOGENEIC CELL THERAPY




- **Precise** gene editing (MAD 7) enables engineering of candidates with synthetic functionalities
- Quality control by ensuring genomic **integrity** is maintained
- Clonal selection of MCB for **homogenous** products, **scalable** process

CELL ENGINEERING ENABLES RAPID PRODUCT ITERATION

Century's Platform allows for transformative product evolution

Fit for purpose tailored functionality








	iNK 1.0	iNK 3.0
Number of Edits	6	12
KO	2	4
Site-specific KI	4	8



illustrative

PIPELINE

Product candidate pipeline across cell platforms and targets in solid and hematologic cancers

Product	iPSC Platform	Targets	Indications	Expected IND Submission	Discovery	Preclinical	Clinical	Collaborator
CNTY-101	iNK	CD19	B-Cell Malignancies	Mid 2022				
CNTY-103	iNK	CD133 + EGFR	Glioblastoma	2023				
CNTY-102	iT	CD19 + CD79b	B-Cell Malignancies	2024				
CNTY-104	iNK/iT	Multi-specific	Acute Myeloid Leukemia	2024				
CNTY-106	iNK/iT	Multi-specific	Multiple Myeloma	2024				

 Solid Tumors  Hematologic Tumors

KEY TAKEAWAYS

We are developing a portfolio of potentially best-in-class, differentiated allogeneic cell therapies that deliver durable responses

We are leveraging our iNK and $\delta\gamma$ iT cell platforms to tackle tumors with unmet medical need

Our comprehensive iPSC-based platform is in place, allowing for rapid iteration

We are well capitalized with platform synergies and operational excellence to advance our portfolio and pipeline in 2022



THANK YOU